ストックスクリーナーアプリを入手
52.15
0.38%
0.20
Bristol Myers Squibb Co (BMY) 最新ニュース
Cresset Asset Management LLC Decreases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Epoch Investment Partners Inc. - MarketBeat
Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable” - Insider Monkey
Do These 3 Healthcare Stocks Need a Checkup? - The Motley Fool
What's Going On With Bristol-Myers Squibb Stock Friday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol Myers Squibb CEO Chris Boerner says company culture was the missing piece of his ‘patent cliff’ plan - Fortune
First Trust Advisors LP Has $212.59 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) – Company AnnouncementFT.com - Financial Times
DEERFIELD MANAGEMENT COMPANY, L.P.'s Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Rx Rundown: Bristol Myers Squibb, Retro Bio, Ionis Pharmaceuticals and more - Medical Marketing and Media
How risky is Bristol Myers Squibb Company stock compared to peers2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - Newser
Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities - Sahm
BMY Gains on News of Continuation of Alzheimer's Disease Study - Finviz
Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech
Scotiabank raises Bristol-Myers Squibb stock price target to $53 on pipeline - Investing.com Nigeria
Invesco Ltd. Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
CW Advisors LLC Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Why Bristol Myers Squibb Company Celegne Contingent stock is a must watch tickerGlobal Markets & Stock Timing and Entry Methods - Newser
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025 - ts2.tech
What's Going On With Bristol-Myers Squibb Shares Wednesday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Shares of Bristol Myers Squibb rise despite delay in clinical trial of promising drug - MarketWatch
Bristol-Myers Squibb stock holds Buy rating at Truist despite trial delay - Investing.com
A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why. - MarketWatch
After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis - BioPharma Dive
Bristol Myers Squibb (BMY) Delays Alzheimer's Drug Trial Results - GuruFocus
Bristol Myers (BMY) Extends ADEPT-2 Study Timeline for Key Alzhe - GuruFocus
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial C - GuruFocus
Bristol Myers (BMY) Bolsters ADEPT-2 Alzheimer's Study with More Participants - GuruFocus
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb - Yahoo Finance
Bristol Myers Stock Jumps As Wall Street Backs Added Enrollment In Alzheimer’s Trial — Retail Calls It ‘Worth A Play’ - Stocktwits
Drug Trial Wins Give Health Care Stocks A Shot - Finimize
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Bristol Myers rises as Alzheimer's trial to enroll more patients - TradingView
M&T Bank Corp Sells 23,588 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers (BMY) Expands ADEPT-2 Study to Address Irregularit - GuruFocus
River Road Asset Management LLC Sells 67,650 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
BMS to enroll more patients in Alzheimer’s psychosis drug trial - Investing.com
Bristol Myers Squibb stock rises after continuing Phase 3 Alzheimer’s study - Investing.com Canada
Loomis Sayles & Co. L P Boosts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Independent Franchise Partners LLP Increases Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Stock Rises on Alzheimer’s Drug Study Update - The Wall Street Journal
Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates - Insider Monkey
BMS Executive: AI to Reshape Pharmaceutical, Biotech Industries - 조선일보
Bristol-Myers Squibb (BMY): Assessing Value After a Recent Short-Term Share Price Rebound - simplywall.st
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Judge Trims but Revives Core Claims in Bristol-Myers $6.7B Suit - USA Herald
BMY: Goldman Sachs Raises Bristol-Myers Squibb Price Target to $57 | BMY Stock News - GuruFocus
Bristol-Myers to Face $6.7 Billion Celgene Deal Payout Suit (1) - Bloomberg Law News
Wealthedge Investment Advisors LLC Buys New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Shelton Capital Management Cuts Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Claret Asset Management Corp Grows Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Faces $6.7 Billion Lawsuit Over Celge - GuruFocus
State Farm Growth Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Judge Rules Bristol Myers Must Face $6.7B Lawsuit Over Delayed Cancer Drug - Claims Journal
Bristol-Myers Must Face Trimmed $6.7B Celgene Investor Suit - Law360
Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast - ts2.tech
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules By Reuters - Investing.com
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules - Yahoo Finance
Judge rejects Bristol Myers Squibb’s bid to dismiss $6.7 billion lawsuit - Investing.com Canada
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock - Yahoo Finance
Trustmark Bank Trust Department Sells 32,341 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
XTX Topco Ltd Buys New Shares in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Unveils Positive Trial Data In Hematology Pipeline - Nasdaq
Bristol Myers Squibb Data At Ash 2025 Showcase Potential Of Hematology Pipeline And Build Momentum For Next Generation Portfolio - TradingView
Bristol Myers (BMY) Showcases Breakthroughs in Hematology at ASH Meeting - GuruFocus
Groupama Asset Managment Cuts Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: A Pivotal Moment for the Pharmaceutical Giant - Ad-hoc-news.de
BioNTech (BNTX) Is Up 7.9% After Raising 2025 Revenue Guidance on Bristol-Myers Collaboration - Yahoo Finance UK
BMY Gains Attention as Bayer Reports FXIa Trial Success - Finviz
Schroder Investment Management Group Increases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
2 Top Dividend Stocks to Buy and Hold - Finviz
1.21%
0.98%
大文字化:
|
ボリューム (24 時間):